PsychU

Exploring Post-Traumatic Stress Disorder: Disease Burden
2023-11-15 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
Post-traumatic stress disorder (PTSD) has a high impact on quality of life, which can negatively affect patient outcomes and relationships with others. These patients also have an increased risk of medical comorbidities and mortality, increasing the burden on the healthcare system and society. This virtual event will further examine the patient, humanistic, clinical, and economic burden of PTSD.

Featuring

David Purselle, MD
Board-certified psychiatrist with over 20 years of clinical experience, Director of Georgia Psychiatric Consultants and an adjunct faculty member at Morehouse School of Medicine

More

Dr. David Purselle is a board-certified psychiatrist with over 20 years of clinical experience working in a variety of settings, including outpatient clinics, emergency rooms, and inpatient units at the Atlanta VA Medical Center, Emory University Hospital, and Grady Hospital. Currently, he is the Director of Georgia Psychiatric Consultants and an adjunct faculty member at Morehouse School of Medicine. He is also involved with several clinical research studies studying the effectiveness of various antidepressants, mood stabilizers, antipsychotics, and lithium.

Dr. Purselle has been recognized as a physician leader in several forums and presented continuing medical education programs at national and local conferences. He has also served as a consultant for major pharmaceutical corporations providing guidance on development of new therapies for a variety of mental illnesses.

Erika Modh, PharmD, BCPS
Medical Science Liaison

David Purselle is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Erika Modh is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Disease State Education: Treatment & Current Treatment Guidelines - Agitation Associated With Alzheimer’s Dementia
2023-11-13 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Virtual Event for PsychU members in DC, Maryland, North Carolina, South Carolina, and Virginia.
In this presentation, topics of discussion are:

Discuss treatment plans are recommended for patients with Alzheimer’s disease
Discuss comprehensive management plan
Discuss unmet needs for treatment of agitation in Alzheimer’s dementia

Featuring

Chris Brodie, PhD (OPDC)
Medical Science Liaison

Justin Wimmer, PharmD
Medical Science Liaison

Speakers Chris Brodie, PhD and Justin Wimmer, PharmD employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Walking The Tight Rope: A Discussion Of Striking The Right Balance In Depression, With A Focus On Norepinephrine
2023-11-09 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
Join us for a PsychU webinar with Drs. Vladimir Maletic, Craig Chepke, and Jason Carter as they discuss the potential role of norepinephrine in Major Depressive Disorder, as part of the monoaminergic theory of depression.

Despite the efficacy of first-line anti-depressant treatments in MDD, many individuals continue to experience unresolved symptoms that may impair their daily functioning and increase the healthcare burden. In fact, the STAR*D study demonstrated approximately one third of patients with MDD achieved remission following treatment with first-line antidepressants, highlighting the need to address unresolved and persistent symptoms of depression.1 Recent studies have shown that norepinephrine, a neurotransmitter which regulates concentration, energy levels, and arousal, may play a crucial role in the persistence of depression symptoms.2

Our webinar aims to provide valuable insights into the complex nature of depression and the potential role of norepinephrine in the pathophysiology of depression.

References:

Rush AJ et al. Am J Psychiatry. 2006;163:1905-1917
Maletic V, et al. Front Psychiatry. 2017;8:42.

Featuring

Vladimir Maletic, MD
Serves as Clinical Professor, Psychiatry/Behavioral Science, University of South Carolina School of Medicine Greenville, SC

More

Vladimir Maletic, MD serves as Clinical Professor, Psychiatry/Behavioral Science, School of Medicine Greenville, SC and has been rated as Best Doctors of the America Registry and Psychiatrist of the year. Dr. Maletic received the Upjohn Achievement Award and Student Council teaching award and faculty award for teaching achievement. He also has received the Medical School Award for Academic Achievement.

Craig Chepke, MD, FAPA
Board-Certified Psychiatrist, Fellow of the American Psychiatric Association, Private practice at Excel Psychiatric Associates in Huntersville, NC, Adjunct Associate Professor of Psychiatry for Atrium Health and University of North Carolina School of Medicine

More

Excel Psychiatric Associates, Atrium Health, and University of North Carolina School of Medicine Dr. Chepke is a Board-Certified psychiatrist and a Fellow of the American Psychiatric Association. He has a private practice at Excel Psychiatric Associates in Huntersville, NC and serves as an Adjunct Associate Professor of Psychiatry for Atrium Health and an Adjunct Assistant Professor of Psychiatry for the University of North Carolina School of Medicine. He has special interests in treatment-resistant and severe mental illness, movement disorders, ADHD, and sleep medicine. Dr. Chepke is a member of the Huntington Study Group and serves on the board of directors for the CURESZ foundation, a nonprofit organization dedicated to improving the lives of people living with Schizophrenia

Jason Carter, PharmD
Senior Medical Science Liaison, Neuroscience Field Medical Affairs

Vladimir Maletic and Craig Chepke are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Jason Carter is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Considerations & Factors For Switching & Augmenting Medications For Major Depressive Disorder
2023-11-07 18:00 - 20:00 (America/New_York) | 21 at the Frederick, 940 4th Ave, Huntington, WV, 25701, United States
Home

Events

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Live Event for PsychU Members in West Virginia.
In this presentation, the objectives are to:

To discuss treatment challenges and guidelines for treating major depressive disorder (MDD)
To consider recommendations from the literature regarding making a treatment change for patients with partial or non-response to current treatment
To understand considerations from the literature regarding switch vs. augmentation as a treatment strategy for patients with partial or non-response
To explore physician determinants of use of antipsychotic treatment augmentation for patients with MDD

Venue

Featuring

Lindsey Wright, PharmD
Medical Science Liaison

Speaker Lindsey Wright, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Virtual Event - Inadequately Treated Major Depressive Disorder (MDD)
2023-11-07 12:00 - 13:00 (America/New_York) | Sheraton Erie Bayfront Hotel, 55 West Bay Drive, Erie, PA, 16507, United States
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a National Virtual Event for all PsychU members.
In this presentation, the objectives are to:

Describe the prevalence of depression in the US
Highlight the burden of MDD
Identify inadequately treated MDD and understand how it impacts patients
Understand which patients are at risk for inadequately treated MDD
Explain MDD treatment strategies

Featuring

Christine Costa, Ph.D., DNP, RN, PMHNP-BC
Psychiatric nurse practitioner, Gateways Hospital and Mental Health Center; Associate Professor at California State University, Long Beach School of Nursing

More

Dr. Costa is a psychiatric nurse practitioner with over 20 years of experience in the health field, currently working for Gateways Hospital and Mental Health Center. She serves as an Associate Professor at California State University, Long Beach School of Nursing. Costa received her Doctor of Philosophy from William Carey University in Hattiesburg, Mississippi, and a Doctor of Nursing Practice from Brandman University in Irvine, California.

Elika Hefazi, PharmD, BCPP
Medical Science Liaison

Speaker Christine Costa, Ph.D., DNP, RN, PMHNP-BC is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Elika Hefazi, PharmD, BCPP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Proposed Roles Of Modulating Norepinephrine In Psychiatric Illnesses
2023-11-03 12:00 - 13:00 (America/New_York) | Sheraton Erie Bayfront Hotel, 55 West Bay Drive, Erie, PA, 16507, United States
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Virtual Event for PsychU members in DC, Maryland, and Virginia.
In this presentation, the objectives are to:
Explore the overlapping monoaminergic pathways
Examine the overlapping monoaminergic circuitry
Describe the brain norepinephrine system including the distribution of adrenergic receptors in the brain
Describe how norepinephrine signaling may directly and indirectly modulate dopamine and serotonin activity
Explore the proposed therapeutic areas where modulation of norepinephrine signaling may be clinically relevant

Featuring

Dennis Sholler, PhD (OPDC)
Senior Medical Science Liaison, CNS

Speaker Dennis Sholler, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Major Depressive Disorder In Chronic Kidney Disease
2023-10-19 18:30 - 21:00 (America/Los_Angeles) | Il Fornaio, 1800 Rosecrans Ave Ste F, Manhattan Beach, CA, 90266, United States
Home

Events

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Live Event for PsychU members in California.
In this presentation, the objectives are to:

Overview of Major Depressive Disorder (MDD) and Chronic Kidney Disease (CKD)/End Stage Renal Disease (ESRD).
Discuss the high prevalence of depression in patients with CKD
Discuss how overlap of symptomatology between MDD and CKD makes diagnosing depression in the setting of CKD challenging.
Discuss the association of MDD with poor outcomes in CKD.
Discuss potential risk factors and mechanism of MDD in CKD.
Discuss the cycle between MDD and ESRD.
Address challenges in MDD management considerations in CKD patients.

Venue

Featuring

Elika Hefazi, PharmD, BCPP
Medical Science Liaison

Marla Dallal, PharmD, RPH
Clinical & Scientific Liaison (Nephrology)

More

Marla Dallal, PharmD, RPH is a Clinical & Scientific Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.

Speakers Elika Hefazi, PharmD, BCPP and Marla Dallal, PharmD, RPH are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Virtual Event - Unmet Needs In Agitation Associated With Alzheimer's Dementia (AAD)
2023-10-19 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Virtual Live Event for PsychU members in Florida and Georgia.
This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis of AAD. We will also explore the potential pathobiological correlations in AAD, describe the clinical and humanistic burden as well as current guidelines for treatments of this complex and prominent complication of an already devastating disease.

Featuring

Marc E. Agronin, MD
Agitation Section Advisor; President of the American Association for Geriatric Psychiatry (AAGP); Senior Vice President for Behavioral Health and Chief Medical Office for the Memory and Research Center at MIND Institute; Affiliate Associate Professor of Psychiatry and Neurology at the University of Miami Miller School of Medicine

Aneta Fornal, PharmD (OPDC)
Medical Science Liaison

Speaker Marc Agronin, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Speaker Aneta Fornal, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Agitation Associated With Alzheimer’s Dementia Disease State Education
2023-10-16 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Virtual Event for PsychU members in DC, Maryland, North Carolina, South Carolina, and Virginia.
In this presentation, topics of discussion are:

Alzheimer’s disease is highly prevalent, under-diagnosed, and predicted to increase significantly in the coming decades due to an aging population
Agitation is a common neuropsychiatric symptom of Alzheimer’s dementia and highly prevalent across patient settings and Alzheimer’s disease severities
The Cohen-Mansfield Agitation Inventory (CMAI) measures the frequency of manifestations of a broad range of agitated behaviors

Featuring

Chris Brodie, PhD (OPDC)
Medical Science Liaison

Justin Wimmer, PharmD
Medical Science Liaison

Speakers Chris Brodie, PhD and Justin Wimmer, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Exploring Post-Traumatic Stress Disorder: Trauma, Trends & Diagnostic Insights
2023-10-16 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
The global effects of trauma, both physiologically and psychologically on individuals, are extensive. This webinar will examine the prevalence of post-traumatic stress disorder (PTSD), explore trauma types, review important screening and diagnostic tools, and delve into the complexities encountered during the initial presentation and subsequent assessment PTSD.

Featuring

Saundra Jain, MA, PsyD, LPC
Adjunct Clinical Affiliate for the School of Nursing at the University of Texas, Austin; Co-founder of WILD-5 Wellness®

More

Saundra Jain is an Adjunct Clinical Affiliate for the School of Nursing at The University of Texas, Austin, Texas. She is very focused on wellness and the impact of positive psychology on client outcomes. She launched a private practice of psychotherapy where she currently provides services for a wide range of mental health issues.

Dr. Jain is a co-creator of the WILD 5 Wellness Program, which combines five elements of wellness (exercise, mindfulness, sleep, social connectedness, and nutrition) into a prescriptive, easy-to-follow wellness program. She is very active in the area of peer-to-peer education, especially in the disease states of depression, bipolar disorder, anxiety disorders, and ADHD. She is the co-creator and co-presenter of a novel interactive workshop addressing the challenges of dealing with psychiatric co-morbidities through the use of psychiatric scales and screeners. She also serves as a member of the Psych Congress Committee providing direction regarding educational gaps & needs for healthcare practitioners in the world of mental health.

Co-founder WILD-5 Wellness®

Elika Hefazi, PharmD, BCPP
Medical Science Liaison

Saundra Jain is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Elika Hefazi is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.  (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

The Impact Of Adherence In Patients With Bipolar I Disorder
2023-10-11 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
Treatment non-adherence is a dilemma in bipolar disorder and is one of the leading challenges in providing effective treatments for people diagnosed with BP I disorder. During our discussion, Dr. Sajatovic and Dr. Goldberg will discuss and define some of these challenges and provide the latest information on treatment-related determinants of adherence. They will also discuss some of the factors important to adherence.

Featuring

Martha Sajatovic, MD
Psychiatrist, Director Neurological and Behavioral Outcomes Center, University Hospital Cleveland Medical Center and Professor, Case Western Reserve University School of Medicine

More

Martha Sajatovic, MD holds the Willard Brown Chair in Neurological Outcomes at University Hospitals Cleveland Medical Center (UH CMC) and the Rocco L. Motto Professorship in Child & Adolescent Psychiatry. Dr. Sajatovic directs the Neurological and Behavioral Outcomes Center at UHCMC/Case Western Reserve University. She has subspecialty certification in Behavioral Neurology & Neuropsychiatry. Dr. Sajatovic is a Professor of Psychiatry and Neurology at Case Western Reserve University School of Medicine (CWRU) in Cleveland, Ohio. Dr. Sajatovic is a researcher, educator, and clinician who has devoted herself to studying and treating traditionally, hard-to-treat populations with central nervous system disorders. Dr. Sajatovic’s research interests have focused on neuropsychiatric outcomes of brain disorders across the life-span, including epilepsy, stroke, Alzheimer’s disease, and other types of dementia and Parkinson’s disease. She has authored or co-authored over 250 peer-reviewed publications and has published over 40 book chapters or books on neuropsychiatric topics. Dr. Sajatovic has been a recipient of the Exemplary Psychiatrist Award bestowed by the National Alliance for the Mentally Ill (NAMI), was a Depression and Bipolar Support Alliance (DBSA) Gerald Klerman Investigator Award winner in 2006 and 2016, and in 2018 received the Rebecca Goldberg Kaufman American Epilepsy Society (AES) Clinical Award in Ethical Neuropsychiatry.

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai

More

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”

Elizabeth DiNapoli, PhD (OPDC)
Senior Medical Science Liaison

More

Dr. DiNapoli earned her PhD from the University of Alabama.

Speakers Martha Sajatovic, MD and Joseph Goldberg, MD are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Elizabeth DiNapoli, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Plasma Concentrations, Pharmacokinetics & Their Clinical Relevance
2023-10-06 12:00 - 13:00 (America/New_York) | Sheraton Erie Bayfront Hotel, 55 West Bay Drive, Erie, PA, 16507, United States
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Virtual Event for PsychU members in DC, Maryland, and Virginia.
Understanding pharmacokinetics is important for determining an effective and safe treatment plan. The objectives of this presentation are to provide an overview of pharmacokinetics (PK) and pharmacodynamics (PD), describe the differences in PK and plasma concentrations of different medication formulations (oral and long-acting injectable (LAI)), and explain the importance of PK and plasma concentrations in the clinical setting.

Featuring

Dennis Sholler, PhD (OPDC)
Senior Medical Science Liaison, CNS

Speaker Dennis Sholler, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Behavioral Health Quality Trends Affecting Payers
2023-10-05 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
The evolving trends of mental healthcare quality measures have a marked impact on payers. Join Molly Burich and Madeline Shurtleff in this discussion that will review current behavioral health quality measures, social determinations of health, and the outcome each has on payers.

Featuring

Molly Burich, (OPDC)
Senior Director, Reimbursement & Health Policy, Government Affairs, Otsuka America Pharmaceutical, Inc.

Madeline Shurtleff, PharmD
Managed Market Liaison

More

Dr. Shurtleff is a clinical pharmacist with experience in managed care and retail pharmacy. She has extensive knowledge in Medicaid and Medicare pharmacy operations and regulatory requirements. Dr. Shurtleff received her Doctor of Pharmacy (PharmD), Business Minor, and Leadership Minor from the University of Rhode Island. She is a licensed pharmacist in Illinois and Arizona.

Molly Burich & Madeline Shurtleff are employees of Otsuka American Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Strategies To Optimize Patient Outcomes In Bipolar-I Disorder: Role Of Long-Acting Injectable Antipsychotics
2023-10-04 12:00 - 13:00 (America/New_York) | Joey’s, 200 Oak Hill Ave, Endicott, NY, 13760, United States
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Virtual Event for PsychU members in Florida and Georgia.
In this presentation, the objectives are to:

Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes
Discuss risk factors for mood episode recurrence, including nonadherence, in patients with bipolar I disorder
Review management strategies, including long-acting injectable antipsychotics (LAIs), to optimize patient outcomes in bipolar I disorder

Featuring

Dante Durand, MD, MBA
Vice Chair of Clinical Services & Associate Professor, Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine; Chief Medical Officer at Jackson Behavioral Health Hospital in Miami, FL.

More

Dr. Dante Durand is an Associate Professor and the Vice-Chair of Clinical Services for the Department of Psychiatry at the University of Miami Miller School of Medicine. He is also the Chief Medical Officer at Jackson Behavioral Health Hospital. Dr. Durand’s area of clinical and research interest is schizophrenia. He has written several scientific articles and is the principal investigator on multiple clinical trials in this area. As faculty member, Dr. Durand has been involved in the education of future generation of psychiatrists and due to his teaching abilities, he has received multiple honors such as the University of Miami, Department of Psychiatry Senior Teaching Award for 5 consecutive years. Dr. Durand is a fellow of the American Psychiatric Association, a member of the American College of Psychiatrists and a board examiner of the American Board of Psychiatry and Neurology.

Aneta Fornal, PharmD (OPDC)
Medical Science Liaison

Speaker Dante Durand, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Speaker Aneta Fornal, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Virtual Event - Unmet Needs In Agitation Associated With Alzheimer's Dementia (AAD)
2023-09-27 12:30 - 13:30 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Virtual Event for PsychU members in Illinois, Kentucky, Missouri, and West Virginia.
This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis of AAD. We will also explore the potential pathobiological correlations in AAD, describe the clinical and humanistic burden as well as current guidelines for treatments of this complex and prominent complication of an already devastating disease.

Featuring

Lindsey Wright, PharmD
Medical Science Liaison

Speakers Kavita Saini, PharmD and Lindsey Wright, PharmD are employees of Otuska Pharmaceutical Development and Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Suicide Awareness & Prevention: PsychU Resource Review & Discussion
2023-09-27 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
The PsychU community is cordially invited to join Drs. Amica Simmons-Yon and Rachel Self as they discuss the critically important topic of suicide awareness and prevention. An overview of resources available on PsychU as well as some of the leading national organizations devoted to suicide awareness and prevention will be provided. Appropriate language, ongoing initiatives, screening tools, and navigation through materials on PsychU will also be highlighted. We all have a role to play in increasing suicide awareness, providing support, and directing individuals in need to potentially life-saving resources. Join us for this opportunity to learn and grow as we all strive to improve our mental health… together!

Featuring

Amica Simmons-Yon, PharmD, PhD
Senior Medical Science Liaison, Neuroscience Field Medical Affairs

Rachel Self, PhD, MS (OPDC)
Medical Science Director, Neuroscience Field Medical Affairs

More

Rachel Self, PhD, MS is a Medical Science Director for Otsuka’s Neuroscience Field Medical Affairs, neuroscientist, & wellness advocate.

Amica Simmons-Yon and Rachel Self are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

If you or someone you know is in crisis,call 988 or the Suicide Prevention Hotline/Lifeline 1-800-273-TALK(8255)or text the Crisis Text Line 741-741

Related Resources

PsychU Suicide Awareness Resources:Suicide Awareness – PsychU

PsychU 988 Webinar:988: What’s The Scoop? A Discussion With Experts In Suicide Prevention & Mental Health – PsychU

Suicide Prevention Resource Center:https://sprc.org/

American Foundation for Suicide Prevention: Become an Advocate:Advocate for suicide prevention | AFSP

PsychU Interview on Stahl’s Clinical Handbook Suicide Prevention Edition:Stahl’s Handbook Suicide Prevention Edition: An Interview With Drs. Christine Moutier & Anthony Pisani – PsychU

988 Update Analysis:One Year After the Launch of 988, the National Suicide and Crisis Hotline Has Received Nearly 5 Million Combined Calls, Texts, and Chats | KFF

PsychU Suicide Prevention Brochure:Download Brochure

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Defining, Clarifying, & Implementing Digital Tools For Mental Health
2023-09-13 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
Digital tools are one of the newest therapeutic modalities for the prevention, management, or treatment of chronic, behavior-modifiable disease.1 In this webinar, Dr. Jake Behrens and Dr. Margaret Emerson will share their expertise in the utilization of digital tools. Together, they will define digital health tools, clarify their potential application in clinical practice, and describe digital tool implementation best practices.

Objectives:
• Define Digital Heath Tools
• Clarify the Application of Digital Tools in Mental Health Treatment
• Outline the Implementation of Digital Tools in Clinical Practice

1 Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics NPJ Digit Med.2020;3:159.

Featuring

Jake Behrens, MD
CEO & Medical Director, Regional Director
Envision ADHD, Brightside Health

Margaret Emerson, DNP, APRN, PMHNP-BC
Clinical Associate Professor at the University of Nebraska Medical Center, Omaha, NE

More

Dr. Margaret Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center, which is the site where she completed her Bachelor, Master and Doctorate degrees. Dr. Emerson has extensive expertise in the development and delivery of Integrated and Collaborative care modalities in a variety of clinical environments. Notably she was one of the first psychiatric mental health nurse practitioners in the state of Nebraska to serve in the psychiatric consultant role. Her research efforts have focused on improving access to care among the underserved patient populations within the integrative environments through the use of mobile technology. As a result of this work she was selected as an expert panelist for the American Psychiatric Association App Advisory Panel. She is regularly an invited speaker and consultant across the United States to disseminate her expertise in integrated care and use of technology. She most recently was awarded an American Rescue Plan Act grant enabling her to develop one of the first integrated care student health clinics in rural Nebraska. This grant focuses on technology and tailored training to promote exposure and interest in these delivery models.

Jason Carter, PharmD
Senior Medical Science Liaison, Neuroscience Field Medical Affairs

Dr. Jake Behrens and Dr. Margaret Emerson are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).
Dr. Jason Carter is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Leadership & Management In Geriatrics
2023-08-03 07:45 - 2023-08-04 15:30 (America/Los_Angeles)
Home

Events

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
August 3-4 & 11, 2023 | Live Virtual Event
Sponsored by Supporting Organization: California Association of Long Term Care Medicine (CALTCM)
This three-day course affords participants the opportunity to spend time in an intensive and highly interactive setting with leaders in the field of geriatric medical management and an exclusive two-month post-course mentorship. Participants are encouraged to think “outside of the box” and consider novel approaches to creating and managing geriatric clinics, practices, and services. A unique feature of the conference is the opportunity for participants to work in small collaborative groups with a faculty mentor to develop and implement an action plan for a management/leadership challenge. CME and CE units are available to all participants, and additional credits are awarded to those who complete a post-course mentorship project.

Register

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Addressing Inequalities In Agitation Among Disinvested Communities With Alzheimer's Disease
2023-07-27 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
Agitation is a complex and challenging neuropsychiatric symptom in Alzheimer’s disease1, and it is associated with increased economic, healthcare, individual, and care partner burden. Unfortunately, agitation associated with Alzheimer’s disease is highly prevalent and poses significant challenges in accessing effective care, particularly for individuals from disinvested and underrepresented ethnicities. The expression of agitation associated with Alzheimer’s Disease is increasing in minority older adults, exacerbating these challenges2. Agitation in Alzheimer’s Disease is associated with increased economic, healthcare, individual, and care partner burden as well.3 In this webinar, our expert speaker will explore the barriers to treatment access and challenges faced by the medical community in delivering equitable care to agitated individuals with Alzheimer’s Disease from diverse backgrounds.

References:

Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015). Assessment and management of behavioral and psychological symptoms of dementia. BMJ (Clinical research ed.), https://doi.org/10.1136/bmj.h369
Babulal, G. M., & Quiroz, Y. T. (2019). Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: Update and areas of immediate need. Alzheimer’s & Dementia, 15(2), 292-312. https://doi.org/10.1016/j.jalz.2018.09.009
Anatchkova, M., & Brooks, A. (2019). Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course. International Psychogeriatrics, 31(9), 1305–1318. https://doi.org/10.1017/S1041610218001898

Featuring

April D. Thames, Ph.D.
Professor of Psychiatry, Chief Psychologist of Adult Division (Psychology) at UCLA Department of Psychiatry and Biobehavioral Sciences

John Awad, MD (OPDC)
Senior Medical Science Liaison

Nneka Okonkwor, PharmD, MBA
Medical Science Liaison

April D. Thames, Ph.D., is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)John Awad, MD and Nneka Okonkwor, PharmD, MBA, are paid employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
US.CORP.X.23.00232

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Home

Events

Exploring Unresolved Symptoms In Major Depressive Disorder (MDD): Potential Role Of Norepinephrine
2023-07-19 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
Join us for a PsychU webinar exploring unresolved symptoms in major depressive disorder (MDD) and the potential role of norepinephrine, as part of the monoaminergic theory of depression.

Despite the efficacy of first-line anti-depressant treatments in MDD, many individuals continue to experience unresolved symptoms that may impair their daily functioning and increase the healthcare burden. In fact, the STAR*D study demonstrated approximately one third of patients with MDD achieved remission following treatment with first-line antidepressants, highlighting the need to address unresolved and persistent symptoms of depression.1 Recent studies have shown that norepinephrine, a neurotransmitter which regulates concentration, energy levels, and arousal, may play a crucial role in the persistence of depression symptoms.2

Please join Drs. Roger McIntyre and John Awad as they discuss the potential role of norepinephrine in depression and the challenges of identifying and treating unresolved depression symptoms. Our webinar aims to provide valuable insights into the complex nature of depression and the potential for treatments to address unresolved symptoms of depression.

References:

Rush AJ et al. Am J Psychiatry. 2006;163:1905-1917
Maletic V, et al. Front Psychiatry. 2017;8:42.

Featuring

Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology, University of Toronto,
Head of the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada

More

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada; Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada, Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois; Professor and Nanshan Scholar at Guangzhou Medical University; Adjunct Professor at College of Medicine in Korea University; and Clinical Professor at State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA, and at Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.

John Awad, MD (OPDC)
Senior Medical Science Liaison

Speaker Roger S. McIntyre, MD, FRCPC is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Speaker John Awad, MD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Webinar Pre-Polling

Please fill out this survey before the webinar!

In your clinical experience, which of the following unmet needs have you recognized with antidepressant treatment (ADT) pharmacotherapy?

Limited specific efficacy with first-line therapies

Intolerable side effects

Inconsistent treatment response

Relatively slow onset of action

Need for second-line treatment modalities
How familiar are you with monoaminergic dysregulation in MDD?

Not at all familiar

Somewhat familiar

Familiar

Very familiar

Extremely familiar
How likely are you to consider modulation of norepinephrine when prescribing treatment to patients with unresolved symptoms?

Never

Rarely

Sometimes

Often

Always
In your clinical practice, what is your preferred second-line treatment strategy when your first-choice ADT is ineffective?

Increase dose and optimize current ADT

Switch to a different ADT (SSRI or SNRI)

Switch to a non-ADT (DNRI)

Stay on same ADT and combine with another ADT (SSRI or SNRI)

Stay on same ADT and augment with a non-ADT (DNRI)

Stay on same ADT and augment with a non-ADT (AAP)
In your clinical practice, what is your preferred adjunctive strategy for patients who have a partial response to monotherapy?

Atypical antipsychotics

Mood stabilizers

Benzodiazepines

Psychotherapy
Which of the following receptors are active during low NE states?

α1A

α1B

α2B

α2C

β2

Δ

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Unmet Needs In Agitation Associated With Alzheimer's Dementia
2023-07-18 18:00 - 20:30 (America/North_Dakota/New_Salem) | Wildfire – Oak Brook, 232 Oakbrook Center, Oak Brook, IL, 60523, United States
Home

Events

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Live Event for PsychU members in Chicago, IL.

This evidence-based review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) for better understanding of the prevalence and challenges in diagnosis and explore the potential pathobiological correlations in AAD. This presentation describes the clinical and humanistic burden and discusses current guidelines for nonpharmacological and pharmacological treatments of this complex and prominent complication of an already devastating disease. It underlines unmet needs for FDA-approved pharmaceutical treatments for agitation to improve care and quality of life for patients suffering from AAD.

Venue

Featuring

Speaker Kavita Saini, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Transition of Care from Hospital to Community (Workbook program)
2023-07-18 18:00 - 19:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Virtual Live Event for PsychU members in New York.
Transition of care from the hospital to the community can be a challenging part of psychiatric care for a variety of reasons. Join this discussion on where some of these gaps are in the process, barriers to these gaps, and discussion on evolving systems focusing on these gaps.

Featuring

Bennett Doughty, PharmD, BCPS, BCPP
Clinical Assistant Professor, Binghamton University School of Pharmacy and Pharmaceutical Science

More

Dr. Bennett Doughty grew up in Winthrop, Maine, and earned his Doctor of Pharmacy degree with honors from the University of Connecticut School of Pharmacy in 2016. Following graduation, Doughty completed two years of residency training at the VA Connecticut Healthcare System in West Haven, CT specializing in psychiatric pharmacy. He is a Board-Certified Pharmacotherapy Specialist (BCPS) and a Board-Certified Psychiatric Pharmacist (BCPP).

Dr. Doughty joined the Binghamton School of Pharmacy and Pharmaceutical Sciences in 2018 as a clinical assistant professor in the Department of Pharmacy Practice. He also serves as a clinical psychiatric pharmacy specialist at the Guthrie Robert Packer Hospital in Sayre, PA, where he has created an integrated outpatient psychiatric clinic within primary care. Dr. Doughty is the program director of the Binghamton University Opioid Overdose Prevention Program (BU OOPP), the director of Binghamton University’s and SUNY Upstate Medical University’s Rural and Underserved Service Track (TRUST), and a Community-Engaged Teaching Fellow, recognized by the Binghamton University Center for Civic Engagement.

Dr. Doughty’s research interests primarily focus on the engagement of patients in substance use disorder treatment but also have expanded to include focus on interprofessional care in underserved communities.

Sara A. Spencer, PharmD, MS, BCGP
Medical Science Liaison

Speaker Bennett Doughty, PharmD, BCPS, BCPP is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Speaker Sara A. Spencer, PharmD, MS, BCGP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Long-Acting Injectables For The Treatment Of Bipolar I Disorder: Relevant Questions From Providers
2023-07-13 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
Join us for this lively discussion with Dr. Joseph Goldberg and Dr. Mauricio Tohen regarding long-acting injectables (LAIs) in the treatment of bipolar I disorder. This moderated session will explore perception, preferences, challenges, and treatment goals for both patients and providers. Discussants will review provider and patient centric perspectives in selecting therapy, plus potential strategies to assess preferences regarding new preventative treatments such as mode of administration, dosing regimen and treatment-related determinants of adherence.

Objectives:

Describe the challenges to long-term treatment and the importance of management options in patients diagnosed with Bipolar I Disorder (BP-I)
Discuss the pros and cons of LAIs for patients living with BP-I, from the provider and patient perspective
Understand strategies to aid in shared decision making between providers and patients when considering LAIs

Featuring

Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai

More

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently “Managing the Side Effects of Psychotropic Medications, 2nd edition” published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly’s “America’s Top Doctors.”

Mauricio Tohen, MD, DrPH, MBA
Chairman, Department of Psychiatry and Behavioral Sciences, Distinguished University Professor, University of New Mexico

More

Mauricio Tohen, MD, DrPH, MBA, is a University Distinguished Professor and Chairman of the Department of Psychiatry at the University of New Mexico Health Science Center, Albuquerque NM. From 2009 to 2013 he was a Professor of Psychiatry and The Krus Endowed Chair in Psychiatry at the University of Texas Health Science Center at San Antonio. Dr. Tohen received his medical degree from the National University of Mexico and his Doctor of Public Health degree in Epidemiology from Harvard University. His postdoctoral training included a residency in Psychiatry at the University of Toronto, a clinical fellowship at McLean Hospital and Harvard Medical School, and a teaching fellowship in Epidemiology at the Harvard School of Public Health. From 1988 to 1997, Dr. Tohen was the Clinical Director of the Bipolar and Psychotic Disorders Program at McLean Hospital. From 1997 to 2008 he was a member of Lilly Research Laboratories reaching the senior-most scientific level of Distinguished Lilly Scholar. In 2009 he joined the University of Texas Health Science Center at San Antonio as the Head of the Division of Mood and Anxiety Disorders. Dr. Tohen received a National Service Award in Psychiatric Epidemiology from the National Institute of Mental Health (NIMH) and Harvard University. He also received a FIRST award from the NIMH, the Pope Award from McLean Hospital, and a NARSAD Young Investigator Award and the Simon Bolivar Award from the American Psychiatric Association. In 2014 he was named by Thomson Reuter’s “The World’s Most Influential Scientific Minds, 2014”. Honorees were the scientists who ranked in the Top 1 percent by citations of their published work in 21 broad fields between 2002 and 2012.

Michael Aldape, PhD
Senior Medical Science Liaison

Joseph Goldberg, MD and Mauricio Tohen, MD, DrPH, MBA are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Michael Aldape, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
US.CORP.X.23.00219

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

The Curious Case Of Metabolic Dysfunction In Schizophrenia: Who’s Susceptible & Why?
2023-06-22 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
A recent article1 published in World Psychiatry evaluated the mid and long term metabolic side effects of 31 antipsychotic drugs and confirmed that antipsychotic drugs differ in their propensity to induce metabolic side effects. Given that patients with schizophrenia often need lifelong treatment, careful consideration should be given when choosing an antipsychotic. Join a multidisciplinary panel including two metabolic-expert psychiatrists, a psychiatric nurse practitioner, and a licensed social worker highlighting:

The heightened metabolic risk in drug-naïve individuals, the added risk when treating with antipsychotics
What cardiometabolic parameters are important to measure (and why)
What can be done to mitigate metabolic risks when considering risk/benefit
Education regarding how the brain and body process sugar and implications for energy production will be discussed
Evolution of metabolic guidelines and where we are headed

Reference:

Burschinski A et al. World Psychiatry 2023; 22 :116-128

Featuring

Christoph Correll, MD
Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.

More

Professor Correll’s research and clinical work focus on the identification, characterization and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness.
He further focuses on psychopharmacology, epidemiology, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.

William Wirshing, MD
Clinical Professor of Psychiatry, Keck USC School of Medicine; and Medical Director of Exodus Recovery, Inc. in Los Angeles, CA

More

Dr. William Wirshing is a Clinical Professor of Psychiatry at the Keck USC School of Medicine and Medical Director of Exodus Recovery, Inc in Los Angeles, where he provides psychiatric and chemical dependency care. His 40-year career has focused on the treatment of persons with schizophrenia and in particular the toxic consequences of putative antipsychotic compounds. Dr. Wirshing and his co-investigators at UCLA and the West Los Angeles VA Medical Center, pioneered the early studies leading to the discovery of metabolic side effects that became a veritable hallmark of the newer class of agents. His findings led to the development of the American Psychiatric Association and American Diabetes Association consensus guideline to appropriately monitor patients on atypical antipsychotic agents.

Michael Townsend, MA, LSW/LCSW
Deputy Chief Executive Officer, Gateway Counseling Center

More

Mr. Townsend, is the Deputy Chief Executive Officer at Gateway Counseling Center where he assists the Chief Executive Officer (CEO) with managing and directing the organization towards its primary objectives, serves as a member of the Boardof Directors, as well as the Chair of Audit Committee of the Mental Health Association in New York, and is also the President of GCC Transportation, LLC, which directs transportation services to the transit disabled and medically frail.

Darcy Leon, PMHNP-BC
Psychiatric Nurse Practitioner

More

Darcy Leon is a psychiatric nurse practitioner currently working in outpatient psychiatry in Tarrytown, NY. She specializes in the treatment of mood disorders, traumatic brain injury, substance use disorders, and treatment-refractory psychiatric illnesses. Darcy also has a specific interest in psychodynamic psychopharmacology, which she employs to better connect patients with the ways their personal experiences interact with medication treatments.

Laura Brennan, PhD (OPDC)
Medical Science Liaison

Christoph Correll, MD, William Wirshing, MD, Michael Townsend MA, LMSW and Darcy Leon, PMHNP-BC are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Laura Brennan, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Early Intervention In Schizophrenia: Targeting Metabolic Dysfunction

On-Demand Webinar November 7, 2017

Increasingly, schizophrenia is considered a medical psychiatric disease. There is evidence that metabolic changes occur within the first episode of psychosis, and within the first few weeks of initiating antipsychotic…

Mental Health & Metabolic Wellness Series: Focus On Weight & Obesity

Video October 9, 2017

During this presentation, Charles Nguyen, MD, provided a brief overview of the obesity epidemic and how obesity may be a contributing factor to other serious medical conditions, including the potential…

New ICD-10-CM Dementia Codes For Agitation In Alzheimer’s Dementia
2023-06-21 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
Effective October 1, 2022, updates to the International Classification of Disease, 10th Revision clinical modification (ICD-10 CM) added new coding specificity options for recording diagnoses of dementia. The expanded codes may be used to capture details of dementia type, severity and more fully identify types of neuropsychiatric symptoms of dementia. This presentation will introduce the improved coding options and describe the coding structure format used in the updated dementia code sections. New code guidance for agitation in Alzheimer’s dementia will be compared to the International Psychogeriatric Association definition of agitation cognitive disorders. Dr. Carolyn Clevenger will discuss use of the codes in practice and the potential implications of the dementia code revisions on providing care for persons living with dementia.

Featuring

Carolyn Clevenger, DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA
Professor of Transformative Clinical Practice, Emory University School of Nursing, Clinical Director and Gerontological Nurse Practitioner at Integrated Memory Care Clinic

More

Carolyn Clevenger DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA, is Professor of Transformative Clinical Practice at the Emory University School of Nursing in Atlanta, Georgia. She serves as Clinical Director and Gerontological Nurse Practitioner at Emory’s Integrated Memory Care Clinic, a patient-centered medical home providing integrated memory care and primary care for persons living with dementia. She is a Past President of the Gerontological Advanced Practice Nurses Association, and Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America.

Mike Crooks, PharmD, BCGP
Senior Long-Term Care Medical Science Liaison

Carolyn Clevenger DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.Mike Crooks, PharmD CGP is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc.

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Pseudobulbar Affect (PBA) In Geriatric & Long-Term Care Patients​
2023-06-14 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
PBA is a neurologic condition that occurs secondary to a variety of otherwise unrelated neurologic conditions and is characterized by sudden, frequent, uncontrollable episodes of laughing and/or crying.1,2 Residents in long-term care settings with PBA symptoms may have different characteristics with their medication usage or behavioral symptoms compared to those residents without PBA symptoms.3,4 In this webinar, our panelists will be reviewing PBA characteristics, neurocircuitry and pathophysiology, PBA prevalence, the impact of PBA on patients and assessment of PBA symptoms.

References:

1. Cummings JL, et al. CNS Spectr. 2006;11(6):1-7
2. Wortzel HS, et al. CNS Drugs. 2008; 22(7):531-545
3. Foley K et al. Int J Geriatr Psychiatry. 2016;31:694-701
4. Zarowitz BJ, et al. Consultant Pharm. 2013;28:713-22

Featuring

Justin Rash, PharmD, BCGP (OPDC)
Senior Medical Science Liaison

Michelle Lavagnino, DrPH(c)
Medical Science Liaison, Long-term Care

Justin Rash and Michelle Lavagnino are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Psychometric Validation of the AASC®: Supporting Early Detection & Improving Caregiver-HCP communication in Agitation Associated With Dementia Due to Alzheimer’s Disease (AAD)

On-Demand Webinar December 3, 2025

In this webinar, Dr. Carolyn Clevenger will provide both background on AASC® tool development and details on AASC® quantitative validation study design and results.

Myths & Misconceptions: Bipolar Disorder

Podcast November 10, 2025

Please join us as Dr. Mauricio Tohen explores common myths and misconceptions about bipolar disorder, from diagnosis and treatment to public perception.

Understanding the Complexity of Attention-Deficit Hyperactivity Disorder

On-Demand Webinar October 16, 2025

Dr. Childress will discuss how the interplay between norepinephrine, dopamine and serotonin plays a critical role in ADHD neurobiology. Lastly, Dr. Childress will summarize the unmet needs of current treatments…

Strategies To Optimize Patient Outcomes In Bipolar I Disorder: The Role Of Long-Acting Injectable Antipsychotics
2023-06-01 18:00 - 21:00 (America/North_Dakota/New_Salem) | Hinterland Brewery, 1001 Lombardi Ave, Green Bay, WI, 54304, United States
Home

Events

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Live Event for PsychU members in the Green Bay, Wisconsin area.

In this presentation, the objectives are to:

Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes
Discuss risk factors for mood episode recurrence, including nonadherence, in patients with bipolar I disorder
Review management strategies, including long-acting injectable antipsychotics (LAIs), to optimize patient outcomes in bipolar I disorder

Venue

Featuring

Heather Fields, PharmD, MPH, BCACP (OPDC)
Medical Science Liaison

Speaker Heather Fields, PharmD, MPH, BCACP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Strategies To Optimize Patient Outcomes In Bipolar I Disorder: The Role Of Long-Acting Injectable Antipsychotics
2023-05-31 18:00 - 20:30 (America/New_York) | Cooper’s Hawk Winery & Restaurant- Centerville, 5220 Cornerstone N Blvd, Centerville, OH, 45440, United States
Home

Events

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a Live Event for PsychU members in the Dayton, OH area.

In this presentation, the objectives are to:

Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes
Discuss risk factors for mood episode recurrence, including nonadherence, in patients with bipolar I disorder
Review management strategies, including long-acting injectable antipsychotics (LAIs), to optimize patient outcomes in bipolar I disorder

Venue

Featuring

Elizabeth DiNapoli, PhD (OPDC)
Senior Medical Science Liaison

More

Dr. DiNapoli earned her PhD from the University of Alabama.

Speaker Elizabeth DiNapoli, PhD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Pharmacokinetics, Plasma Concentration & Clinical Relevance
2023-05-25 18:00 - 20:00 (America/Chicago) | YaYa’s Eurobistro, 7021 W 135th Street, Overland Park, KS, 66223, United States
Home

Events

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
This is a live event for PsychU members in Overland Park, Kansas area.

Pharmacokinetics refers to the study of how drugs are processed by the body. These processes play an important role in mental health treatments, and can vary due to several factors, ultimately impacting treatment of mental health. In this presentation, the speaker will first provide an overview of pharmacokinetics and pharmacodynamics. Then, the speaker will discuss the differences between pharmacokinetics based on different medication formulations, including the differences between oral and long-acting injectable formulations. Finally, the importance of pharmacokinetics and plasma concentration monitoring will be discussed as it relates to the clinical setting.

Venue

Featuring

Steven Stoner, PharmD
Associate Dean for Student Affairs/Clinical Professor, University of Missouri-Kansas City School of Pharmacy

More

Steven Stoner, PharmD, BCPP, is Board Certified in Psychiatric Pharmacy. He is the associate dean of Student Affairs and a Clinical Professor at the UMKC School of Pharmacy. He received his PharmD from the University of Nebraska College of Pharmacy. Dr. Stoner completed a postdoctoral residency in psychiatric pharmacy practice and administration and a fellowship at Western Missouri Mental Health Center in Kansas City, Missouri.

Maria Perez, PharmD, AAHIVP
Medical Science Liaison – Digital Therapeutics

Speaker Steven Stoner, PharmD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC).Moderator Maria Perez, PharmD, AAHIVP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

PSYCHU PROGRAM ATTENDANCE ELIGIBILITY REQUIREMENTS
PsychU is supported by Otsuka Pharmaceutical Developmental & Commercialization Inc., Otsuka America Pharmaceutical, Inc., and Lundbeck, L.L.C., committed supporters of the mental health treatment community; as such, PsychU is governed in accordance with the PhRMA Code on Interactions with Healthcare Professionals attendance at educational programs.
PSYCHU MEMBERSHIP ELIGIBILITY
In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at PsychU educational programs is limited to appropriate attendees (e.g., physician, clinical professional, current medical school student, care manager, advocate, recovery coach or an executive and manager of an organization) whose primary role is to provide, manage, finance, study, or regulate mental health services for adult patients.
NOTE: Otsuka Pharmaceutical Development & Commercialization Inc. (OPDC) reserves the right to decline membership to individuals who OPDC determines do not meet the certification requirements.
MEMBERSHIP & REGISTRATION
Membership is required to attend PsychU programs. Membership is free to all relevant mental health professionals as described above. If you are not currently a member of PsychU, you will need to become a member before you can register to attend an event. Registration for PsychU Live Events will be closed 2 business days prior to the date of the event. No walk-ins will be permitted to attend PsychU Live Events. To become a member and register for a PsychU Program, please visit https://www.PsychU.org/.
ATTENDANCE LIMITATIONS
PsychU declines attendance after a healthcare professional has attended a pre-determined number of programs, has attended multiple programs on the same topic or is outside the appropriate specialty for PsychU programs, to avoid any appearance of impropriety between OPDC and the healthcare professional. This measure protects the healthcare professional as well as OPDC. If you have any questions, please do not hesitate to reach out to the OPDC Ethics and Compliance Department at E&CHelpline@otsuka-us.com.
MEAL REPORTING
The value of all meals provided at PsychU events will be attributed to attendees and reported in accordance with relevant federal and state laws.

Faces Of Depression In Primary Care: Depression Symptomology & Functional Outcomes From Early To Late Adulthood
2023-05-24 12:00 - 13:00 (America/New_York)
Home

Events

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:

About This Event

Virtual Event – Addressing Unresolved Symptoms of Major Depressive Disorder
Depression is a common disorder and leading cause of disability worldwide, which impacts an estimated 280 million individuals or ~5% of the adult population.1 Primary care clinicians are often the first access point for individuals experiencing behavioral health symptoms, particularly depression.2 Although they have the training and expertise required to address mental illnesses, differences in presentation across the lifespan and presence of medical comorbidities can complicate recognition and effective treatment of major depressive disorder.
In this Faces of Depression webinar, Dr. Beth DiNapoli moderates an enlightening discussion on various presentations of depression across the adult lifespan with primary care physician and clinical researcher Dr. C. Brendan Montano. They will share perspectives on the role of primary care in identifying, assessing, and managing major depressive disorder across the lifespan. An emphasis on some of the unique complexities within the primary care landscape and an examination of the burden of disease with respect to functional outcomes will be provided. Finally, the various treatments for depression and the role they may play in overall depression improvement and functionality will be highlighted. Join us for this opportunity to learn and grow as we all strive to improve our mental health …. together!

References:

1. World Health Organization 2022 website: https://www.who.int/news-room/fact-sheets/detail/depression
2. Jetty et al. 2021 Assessing Primary Care Contributions to Behavioral Health: A Cross-sectional Study Using Medical Expenditure Panel Survey; Journal of Primary Care & Community Health Volume 12: 1–6.

Featuring

C. Brendan Montano, MD, PC
Director and Principal Investigator for Connecticut Clinical Research in Cromwell, Connecticut

More

Brendan Montano, MD, is the owner and medical director of Montano Wellness, LLC, and director of and a principal investigator for CT Clinical Research, all in Cromwell, Connecticut. Dr Montano is also an attending physician at Middlesex Memorial Hospital in Middletown, Connecticut, a clinical instructor at Springfield College in Springfield, Massachusetts, and a primary care section advisor online for PsychU. He earned his medical degree from Albany College in Albany, New York. He completed his residency in internal medicine at Saint Francis Hospital and Medical Center in Hartford, Connecticut. Dr Montano has served as a principal investigator for over 120 clinical trials to evaluate the safety and efficacy of novel therapeutics for indications such as attention-deficit/hyperactivity disorder, major depressive disorder, and many other psychiatric and neurologic conditions. He is an editorial board member of The Primary Care Companion for CNS Disorders.

Elizabeth DiNapoli, PhD (OPDC)
Senior Medical Science Liaison

More

Dr. DiNapoli earned her PhD from the University of Alabama.

C. Brendan Montano is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.(OPDC). Beth DiNapoli is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Related Resources

Assessing Cognitive Impairment, Depression, & Functionality In Older Adults

Interview August 10, 2022

Cognitive impairment, depression, and functional decline are all common in older adults. Therefore, it is important for care providers to understand how to screen/evaluate for each of these domains in…

Patient Health Questionnaire 9 (PHQ-9)

Downloadable Resource October 30, 2017

The Patient Health Questionnaire 9 is a self-administered 9-item scale for assessing and monitoring depression severity. It is derived from the depression questions within the full Patient Health Questionnaire (PHQ)….
